Looking to the Future in an Unprecedented Time for Cancer Drug Development

Over the past several years sustained commitment to cancer research has been translated into therapeutic advances across a broad range of drug and biologic products. The magnitude of benefit observed with many of these cancer therapies has enabled the Office of Hematology and Oncology Products at the FDA to proactively utilize regulatory programs to expedite the delivery of safe and effective therapies to patients. How did we get here, and what can the cancer drug development community do to continue to bring tangible benefit to cancer patients? (Source: Seminars in Oncology)

from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader http://ift.tt/1lh1Smc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1ZCJ5om
via IFTTT